Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys

The comparative pharmacokinetics of alprazolam and lorazepam were evaluated in African Green Monkeys and in healthy male human volunteers. Six monkeys received a single 250 µg/kg oral dose of alprazolam and of lorazepam on two separate occasions. Mean kinetic values for the two drugs, respectively, were: elimination half-life, 5.7 and 1.7 h; oral clearance, 5.5 and 40.2 ml/min/kg. Healthy male volunteers (n=22) received a single 1 mg oral dose of alprazolam; another group (n=24) received a single 2 mg oral dose of lorazepam. Mean values of elimination half-life in humans (11.5 and 12.4 h, for alprazolam and lorazepam, respectively) were substantially longer than corresponding values in the primate animal model, and human values of clearance (0.85 and 1.40 ml/min/kg) likewise were much lower. However, in humans, kinetic differences between the two drugs were much smaller than in the primate animals. Thus comparative studies of the behavioral effects of these two drugs in African Green Monkeys should utilize relative dosages that reflect the pharmacokinetic properties of the drugs in that species. Use of dosage ratios analogous to those used in humans may lead to results that cannot be extrapolated to humans.

[1]  L. Harris,et al.  Dependence on tetrahydrocannabinol in rhesus monkeys. , 1986, The Journal of pharmacology and experimental therapeutics.

[2]  J. Miller,et al.  Antipyrine plasma half-life. In vivo indicator of oxidative metabolic capability in Rhesus monkeys (Macaca mulatta). , 1978, Pharmacology.

[3]  R. Roth,et al.  Chronic treatment with haloperidol or fluphenazine decanoate: regional effects on dopamine and serotonin metabolism in primate brain. , 1982, Journal of Pharmacology and Experimental Therapeutics.

[4]  D. Greenblatt,et al.  Clinical pharmacokinetics (second of two parts). , 1975, The New England journal of medicine.

[5]  B. Dvorchik,et al.  On the antipyrine test in laboratory animals. Studies in the dog and monkey. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[6]  D. Greenblatt,et al.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. , 1980, Journal of pharmaceutical sciences.

[7]  S. Gee,et al.  Antipyrine Plasma Half-Life , 1978 .

[8]  H. Boxenbaum Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  D. Greenblatt,et al.  Pharmacokinetics in clinical practice , 1985 .

[10]  R. Roth,et al.  Precipitated diazepam withdrawal elevates noradrenergic metabolism in primate brain. , 1985, European journal of pharmacology.

[11]  D. Greenblatt,et al.  Alprazolam kinetics in the elderly. Relation to antipyrine disposition. , 1983, Archives of general psychiatry.

[12]  D. Greenblatt,et al.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. , 1978, Journal of chromatography.

[13]  D. Greenblatt,et al.  Analysis of lorazepam and its glucoronide metabolite by electron-capture gas—liquid chromatography , 1978 .

[14]  D. Greenblatt,et al.  Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans , 1979 .

[15]  D. Greenblatt,et al.  Automated gas chromatographic determination of plasma alprazolam concentrations. , 1983, Journal of clinical psychopharmacology.

[16]  R. Griffiths,et al.  Responding maintained by cocaine or d-amphetamine under fixed-interval schedules in baboons. , 1980, Drug and alcohol dependence.

[17]  D. Greenblatt,et al.  Concentration‐independent plasma protein binding of benzodiazepines , 1983, The Journal of pharmacy and pharmacology.

[18]  D. Greenblatt,et al.  Drug therapy. Clinical Pharmacokinetics (first of two parts). , 1975 .

[19]  D E Redmond,et al.  Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. , 1979, Life sciences.

[20]  D. Greenblatt,et al.  Clinical Pharmacokinetics of the Newer Benzodiazepines , 1983, Clinical pharmacokinetics.

[21]  D. Greenblatt,et al.  Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. , 1989, The Journal of pharmacology and experimental therapeutics.